Clinical trial
Iressa as Second Line Therapy in Advanced NSCLC-Asia
NCT00478049 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00478049 |
|---|---|
| Title | Iressa as Second Line Therapy in Advanced NSCLC-Asia |
| Official title | A Randomized, Open Label, Parallel Group, Regional, Multicenter, Phase III Study of Oral Gefitinib (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic Recurrent Non Small Cell Lung Cancer Who Have Previously Received Platinum Based Chemotherapy (ISTANA) |
| Acronym | ISTANA |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | NSCLC |
| Intervention type | Drug |
| Interventions | Gefitinib, Docetaxel |
| Enrollment | 163 |
| Start date | Sep 1, 2005 |
| Primary completion | May 1, 2007 |
| Completion | Feb 1, 2009 |
| First posted | May 24, 2007 |
| Last update posted | Jun 6, 2012 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: